Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. / Rasmussen, Gregers Brünnich; Håkansson, Katrin E; Vogelius, Ivan R; Rasmussen, Jacob H; Friborg, Jeppe T; Fischer, Barbara M; Schumaker, Lisa; Cullen, Kevin; Therkildsen, Marianne H; Bentzen, Søren M; Specht, Lena.
I: Acta Oncologica, Bind 56, Nr. 11, 2017, s. 1562-1570.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma
AU - Rasmussen, Gregers Brünnich
AU - Håkansson, Katrin E
AU - Vogelius, Ivan R
AU - Rasmussen, Jacob H
AU - Friborg, Jeppe T
AU - Fischer, Barbara M
AU - Schumaker, Lisa
AU - Cullen, Kevin
AU - Therkildsen, Marianne H
AU - Bentzen, Søren M
AU - Specht, Lena
PY - 2017
Y1 - 2017
N2 - OBJECTIVE: To identify a failure site-specific prognostic model by combining immunohistochemistry (IHC) and molecular imaging information to predict long-term failure type in squamous cell carcinoma of the head and neck.PATIENT AND METHODS: Tissue microarray blocks of 196 head and neck squamous cell carcinoma cases were stained for a panel of biomarkers using IHC. Gross tumor volume (GTV) from the PET/CT radiation treatment planning CT scan, maximal Standard Uptake Value (SUVmax) of fludeoxyglucose (FDG) and clinical information were included in the model building using Cox proportional hazards models, stratified for p16 status in oropharyngeal carcinomas. Separate models were built for time to locoregional failure and time to distant metastasis.RESULTS: Higher than median p53 expression on IHC tended toward a risk factor for locoregional failure but was protective for distant metastasis, χ2for difference p = .003. The final model for locoregional failure included p53 (HR: 1.9; p: .055), concomitant cisplatin (HR: 0.41; p: .008), β-tubulin-1 (HR: 1.8; p: .08), β-tubulin-2 (HR: 0.49; p: .057) and SUVmax (HR: 2.1; p: .046). The final model for distant metastasis included p53 (HR: 0.23; p: .025), Bcl-2 (HR: 2.6; p: .08), SUVmax (HR: 3.5; p: .095) and GTV (HR: 1.7; p: .063).CONCLUSIONS: The models successfully distinguished between risk of locoregional failure and risk of distant metastasis, which is important information for clinical decision-making. High p53 expression has opposite prognostic effects for the two endpoints; increasing risk of locoregional failure, but decreasing the risk of metastatic failure, but external validation of this finding is needed.
AB - OBJECTIVE: To identify a failure site-specific prognostic model by combining immunohistochemistry (IHC) and molecular imaging information to predict long-term failure type in squamous cell carcinoma of the head and neck.PATIENT AND METHODS: Tissue microarray blocks of 196 head and neck squamous cell carcinoma cases were stained for a panel of biomarkers using IHC. Gross tumor volume (GTV) from the PET/CT radiation treatment planning CT scan, maximal Standard Uptake Value (SUVmax) of fludeoxyglucose (FDG) and clinical information were included in the model building using Cox proportional hazards models, stratified for p16 status in oropharyngeal carcinomas. Separate models were built for time to locoregional failure and time to distant metastasis.RESULTS: Higher than median p53 expression on IHC tended toward a risk factor for locoregional failure but was protective for distant metastasis, χ2for difference p = .003. The final model for locoregional failure included p53 (HR: 1.9; p: .055), concomitant cisplatin (HR: 0.41; p: .008), β-tubulin-1 (HR: 1.8; p: .08), β-tubulin-2 (HR: 0.49; p: .057) and SUVmax (HR: 2.1; p: .046). The final model for distant metastasis included p53 (HR: 0.23; p: .025), Bcl-2 (HR: 2.6; p: .08), SUVmax (HR: 3.5; p: .095) and GTV (HR: 1.7; p: .063).CONCLUSIONS: The models successfully distinguished between risk of locoregional failure and risk of distant metastasis, which is important information for clinical decision-making. High p53 expression has opposite prognostic effects for the two endpoints; increasing risk of locoregional failure, but decreasing the risk of metastatic failure, but external validation of this finding is needed.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Biomarkers/analysis
KW - Carcinoma, Squamous Cell/diagnostic imaging
KW - Chemoradiotherapy
KW - Clinical Decision-Making
KW - Female
KW - Follow-Up Studies
KW - Head and Neck Neoplasms/diagnostic imaging
KW - Humans
KW - Male
KW - Middle Aged
KW - Molecular Imaging/methods
KW - Neoplasm Recurrence, Local/diagnostic imaging
KW - Positron Emission Tomography Computed Tomography
KW - Prognosis
KW - Retrospective Studies
KW - Survival Rate
U2 - 10.1080/0284186X.2017.1364870
DO - 10.1080/0284186X.2017.1364870
M3 - Journal article
C2 - 28840766
VL - 56
SP - 1562
EP - 1570
JO - Acta Oncologica
JF - Acta Oncologica
SN - 1100-1704
IS - 11
ER -
ID: 193898036